ProFibrix Obtains Government Loan of up to EUR 5 Million (~ US$7.4 Million) to Support Clinical Development of its Lead Hemostasis Product Fibrocaps(TM)

LEIDEN, The Netherlands and SEATTLE, Washington, January 7 - ProFibrix B.V., a leader in the development of innovative
products for hemostasis and regenerative medicine, today announced that
SenterNovem, an agency of the Dutch Ministry of Economic Affairs, has granted
the company a loan under its new Innovation Credit scheme of potentially up
to EUR 5 million to finance the further clinical development of its unique
new hemostat Fibrocaps(TM).

The loan consists of an initial commitment of EUR 2.75
million, with the possibility to call on an additional EUR 2.25 million when
and if certain development milestones are met.

Jaap Koopman, PhD, Chief Executive Officer of ProFibrix said:
"On the back of our recent successful B round in which we raised EUR 8
million (~ US $11 million), we are very pleased to further solidify the
financial basis of ProFibrix. Loans under this special scheme are awarded to
innovative projects with a strong commercial potential. This loan will be
instrumental in financing the Phase II and III development of our lead
product Fibrocaps."

Fibrocaps is based on a mixture of two essential blood
clotting proteins, fibrinogen and thrombin, and is a unique dry powder
topical tissue sealant that rapidly stops bleeding after or during surgery.
Fibrocaps has major advantages over existing liquid tissue sealants: it is
ready for immediate use, is stable at room temperature, highly effective and
fast acting. Fibrocaps is currently in a Phase II clinical trial in the
Netherlands with results expected early in 2010.

ProFibrix expects to submit an Investigational New Drug
Application (IND) for Fibrocaps to the U.S. Food and Drug Administration in
the first half of 2010, and to conduct a combined phase II/III pivotal study
in various surgical indications.

ProFibrix will present at the Biotech Showcase, which takes
place in conjunction with the JP Morgan Healthcare Conference in San
Francisco, on Tuesday, January 12, 2010 at 8:40 a.m. in the "Regimental" room
at the Marines' Memorial Club & Hotel, 609 Sutter Street, San Francisco.

About ProFibrix

ProFibrix (www.ProFibrix.com) was founded in 2004 and
is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle,
WA, USA The company leverages its expertise in fibrinogen technology to
develop and market innovative products for the hemostasis and regenerative
medicine markets. Human fibrinogen plays a pivotal role in blood clotting and
tissue healing. ProFibrix is led by a team with extensive commercial,
clinical and scientific experience in the hemostasis field.

About SenterNovem and the Innovation Credit scheme

SenterNovem (www.senternovem.nl) is an agency of the
Dutch Ministry of Economic affairs that promotes sustainable development and
innovation with various financial instruments. The Innovation Credit
(innovatiekrediet) scheme is aimed at supporting high risk, and commercially
attractive development projects with an interest-bearing loan of which
repayment is waived if the project fails.

ProFibrix B.V., Jaap Koopman, Ph.D., CEO, Tel: +31(0)6-21628475, E-mail: j.koopman at profibrix.com; ProFibrix Inc., Jan Ohrstrom, MD, COO, Tel: +1-2069105404, E-mail: j.ohrstrom at profibrix.com